Comparison of Expanded Hemodialysis and Other Dialysis Techniques Using Theranova and HFR Filters for Toxin Removal in Chronic Renal Failure

What this Trial Is About

Researchers are comparing different hemodialysis techniques to understand their effectiveness in removing uremic toxins in patients with chronic renal failure. The study focuses on expanded hemodialysis (HDx) using the Theranova 400 filter compared with high-flux hemodialysis (HF-HD), online hemodiafiltration (OL-HDF), and hemodiafiltration with endogenous reinfusion (HFR). The goal is to see if HDx offers benefits, especially for more malnourished and frail patients, over other dialysis methods. This observational study analyzes data from about 50 patients treated between 2018 and 2022 at a specialized dialysis center. Patients are grouped based on the dialysis technique used: HDx with Theranova filter, HFR with HFR17 filter, OL-HDF, or HF-HD. Each group has at least 10 patients who have been on dialysis for at least six months and have used the same filter continuously for 12 months. All patients receive standard medical therapy and dialysis care as part of routine clinical practice. The study collects and compares data on the removal of small and medium molecular weight toxins, inflammation control, and erythropoietin resistance over a 12-month period. Participants' clinical data, including blood tests and relevant health events, are collected retrospectively from medical records in a pseudonymized format. No additional treatments or study-specific visits are required. Data collection and analysis will take place over approximately 18 months following ethics approval, using statistical methods to evaluate differences between dialysis methods at baseline, 3 months, and 12 months. The study monitors the safety and effectiveness of these dialysis techniques in real-world clinical settings.

Comparison of Hemodialysis Techniques in the Removal of Uremic Toxins in Chronic Renal Failure